Эмпирическая терапия пациентов с симптомами нижних мочевых путей на фоне ДГПЖ: результаты многоцентрового наблюдательного исследования МЕРКУРИЙ
Список литературы
- Клинические рекомендации МЗ РФ «Доброкачественная гиперплазия предстательной железы». Год утверждения 2024 г.
- Djavan, B., et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology, 2004. 64: 1081.
- Nasu K, Moriyama N, Kawabe K, et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol. 1996;119(5):797-803.
- Tatemichi S., Kobayashi K., Maezawa A. A1-adrenoceptor subtype selectivity and organ specifi city of silodosin (KMD- 3213). Yakugaku Zasshi. 2006;126:209–216.
- EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS) 2025.
- Choi WS, Cho MC, Lee JW, et al. Efficacy and safety of silodosin in the treatment of lower urinary tract symptoms in elderly men taking antihypertensive medications. Prostate Int. 2017;5(3):113-118.
- Morganroth J. Effects of the Selective α1A-Adrenoceptor Antagonist Silodosin on ECGs of Healthy Men in a Randomized, Double-Blind, Placeboand Moxifloxacin-Controlled Study Clin Pharmacol & Therapeutics. 2010;87(5):609-613.
- Chapple CR, Montorsi F, Tammela TL, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59(3):342-352.
- Montorsi F. Profile of silodosin. Eur Urol Suppl 2010;9(4):491-495.
- Cui Y, Zong H, Zhang Y. The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis. Int Urol Nephrol. 2012 Dec;44(6):1601-9.
- Novara G. et al. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data. Br J Urol Int. 2015;115(5);802-814.
- Yuan C, Jian Z, Ma Y, et al. Systematic review and meta-analysis of efficacy and safety of silodosin in treatment of benign prostatic hyperplasia patients with lower urinary tract symptoms. Research Square; 2020. DOI: 10.21203/rs.2.23577/v1.
- Osman NI, Chapple CR, Tammela TL, Eisenhardt A, Oelke M. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH. World J Urol. 2015 May;33(5):697-706.
- https://go.drugbank.com/drug-interaction-checker дата обращения 18.06.2025
- Общая характеристика лекарственного препарата Урорек от 07.08.2023, http://eec.eaeunion.org/
- Зимичев А.А., Гусев Д.О., Лукьянова Д.Ю. Оценка эффективности применения препарата силодозин 8 мг в терапии коморбидных пациентов c СНМП/ДГПЖ. Урология. 2022. №6. С. 36-40.
- Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009 Jun;181(6):2634-40.
- Montorsi F, Gandaglia G, Chapple C, Cruz F, Desgrandchamps F, Llorente C. Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study). Int J Urol. 2016 Jul;23(7):572-9.
НАШИ ПАРТНЕРЫ
